Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):80–85. doi: 10.1128/aac.40.1.80

Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.

L H Wang 1, M Schultz 1, S Weller 1, M L Smiley 1, M R Blum 1
PMCID: PMC163061  PMID: 8787884

Abstract

A randomized, double-blind study was conducted to evaluate the safety and pharmacokinetics of acyclovir following multiple-dose oral administration of valaciclovir (three times a day for 8 days) in geriatric volunteers (65 to 83 years of age). Pharmacokinetic evaluation was performed for three groups: normotensive subjects given 500-mg doses of valaciclovir (n = 11), normotensive subjects given, 1,000-mg doses of valaciclovir (n = 9), and thiazide diuretic-treated hypertensive subjects given 500-mg doses of valaciclovir (n = 9). Valaciclovir, the l-valyl ester of acylclovir, was rapidly absorbed and converted to acyclovir, with plasma valaciclovir concentrations generally undetectable or < or = 0.4 microgram/ml. The peak concentration of drug in plasma (Cmax) for acyclovir occurred at 1 to 2 h, and the half-life of acyclovir was 3 to 4 h in all three elderly groups. The Cmax and area under the concentration-time curve from 0 h to infinity (AUC0-infinity) values of acyclovir obtained on days 1 and 8 indicated no unexpected accumulation at steady state. The steady-state acyclovir Cmax (4.30 and 5.98 micrograms/ml) and daily AUC0-infinity (44 and 74 h.micrograms/ml) following dosing of valaciclovir (500 and 1,000 mg) three times a day were two to three times greater than those expected after high-dose oral acyclovir treatment (800 mg, five times daily). There were no valaciclovir-related changes or abnormalities in safety parameters and no reports of serious adverse experiences in these elderly volunteers. The plasma acyclovir concentration-time curves for the hypertensive and normotensive (500-mg valaciclovir treatment) elderly groups were almost superimposable, and acyclovir pharmacokinetic parameters for the two groups were not significantly different, indicating that concomitant thiazide diuretics do not alter acyclovir pharmacokinetics following valaciclovir dosing in the elderly. Compared with historical data for younger volunteers (creatinine clearance [CLCR] > 75 ml/min/1.73 m2), the elderly subjects (CLCR = 40 to 65 ml/min/1.73 m2) showed higher (approximately 15 to 20%) mean Cmaxs and higher (approximately 30 to 50%) mean AUC(0-infinity)s of acyclovir (P < 0.01), which were consistent with age-related decreases in CLCR. The increased acyclovir exposure from valaciclovir dosing will permit reduced dosing frequency and may result in improved efficacy in the management of herpesvirus diseases.

Full Text

The Full Text of this article is available as a PDF (229.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balfour H. H., Jr, Bean B., Laskin O. L., Ambinder R. F., Meyers J. D., Wade J. C., Zaia J. A., Aeppli D., Kirk L. E., Segreti A. C. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983 Jun 16;308(24):1448–1453. doi: 10.1056/NEJM198306163082404. [DOI] [PubMed] [Google Scholar]
  2. Bean B., Braun C., Balfour H. H., Jr Acyclovir therapy for acute herpes zoster. Lancet. 1982 Jul 17;2(8290):118–121. doi: 10.1016/s0140-6736(82)91090-x. [DOI] [PubMed] [Google Scholar]
  3. Beutner K. R., Friedman D. J., Forszpaniak C., Andersen P. L., Wood M. J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995 Jul;39(7):1546–1553. doi: 10.1128/aac.39.7.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Biron K. K., Elion G. B. In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrob Agents Chemother. 1980 Sep;18(3):443–447. doi: 10.1128/aac.18.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Blum M. R., Liao S. H., de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med. 1982 Jul 20;73(1A):186–192. doi: 10.1016/0002-9343(82)90088-2. [DOI] [PubMed] [Google Scholar]
  6. Cobo M. Reduction of the ocular complications of herpes zoster ophthalmicus by oral acyclovir. Am J Med. 1988 Aug 29;85(2A):90–93. [PubMed] [Google Scholar]
  7. Gehan E. A., George S. L. Estimation of human body surface area from height and weight. Cancer Chemother Rep. 1970 Aug;54(4):225–235. [PubMed] [Google Scholar]
  8. Huff J. C., Bean B., Balfour H. H., Jr, Laskin O. L., Connor J. D., Corey L., Bryson Y. J., McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29;85(2A):84–89. [PubMed] [Google Scholar]
  9. Laskin O. L., de Miranda P., King D. H., Page D. A., Longstreth J. A., Rocco L., Lietman P. S. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother. 1982 May;21(5):804–807. doi: 10.1128/aac.21.5.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Loeser J. D. Herpes zoster and postherpetic neuralgia. Pain. 1986 May;25(2):149–164. doi: 10.1016/0304-3959(86)90089-8. [DOI] [PubMed] [Google Scholar]
  11. Mawer G. E., Lucas S. B., Knowles B. R., Stirland R. M. Computer-assisted prescribing of kanamycin for patients with renal insufficiency. Lancet. 1972 Jan 1;1(7740):12–15. doi: 10.1016/s0140-6736(72)90005-0. [DOI] [PubMed] [Google Scholar]
  12. McKendrick M. W., McGill J. I., Bell A. M., Hickmott E., Burke C. Oral acyclovir for herpes zoster. Lancet. 1984 Oct 20;2(8408):925–925. doi: 10.1016/s0140-6736(84)90678-0. [DOI] [PubMed] [Google Scholar]
  13. Peterslund N. A., Seyer-Hansen K., Ipsen J., Esmann V., Schonheyder H., Juhl H. Acyclovir in herpes zoster. Lancet. 1981 Oct 17;2(8251):827–830. doi: 10.1016/s0140-6736(81)91102-8. [DOI] [PubMed] [Google Scholar]
  14. Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
  15. Ragozzino M. W., Melton L. J., 3rd, Kurland L. T., Chu C. P., Perry H. O. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982 Sep;61(5):310–316. doi: 10.1097/00005792-198209000-00003. [DOI] [PubMed] [Google Scholar]
  16. Richards D. M., Carmine A. A., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1983 Nov;26(5):378–438. doi: 10.2165/00003495-198326050-00002. [DOI] [PubMed] [Google Scholar]
  17. Shepp D. H., Dandliker P. S., Meyers J. D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med. 1986 Jan 23;314(4):208–212. doi: 10.1056/NEJM198601233140404. [DOI] [PubMed] [Google Scholar]
  18. Weller S., Blum M. R., Doucette M., Burnette T., Cederberg D. M., de Miranda P., Smiley M. L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993 Dec;54(6):595–605. doi: 10.1038/clpt.1993.196. [DOI] [PubMed] [Google Scholar]
  19. Weller T. H. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983 Dec 1;309(22):1362–1368. doi: 10.1056/NEJM198312013092205. [DOI] [PubMed] [Google Scholar]
  20. Whitley R. J., Gnann J. W., Jr Acyclovir: a decade later. N Engl J Med. 1992 Sep 10;327(11):782–789. doi: 10.1056/NEJM199209103271108. [DOI] [PubMed] [Google Scholar]
  21. de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES